Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial.
Saved in:
| Title: | Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. |
|---|---|
| Authors: | Bolli R; Department of Medicine, Division of Cardiovascular Medicine, University of Louisville, School of Medicine, Louisville, Kentucky, USA., Perin EC; Division of Cardiology Research, Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, USA., Willerson JT; Division of Cardiology Research, Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, USA., Yang PC; Department of Medicine and Cardiovascular Institute, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA., Traverse JH; Department of Medicine, Cardiovascular Division, Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, and University of Minnesota School of Medicine, Minneapolis, Minnesota, USA., Henry TD; The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, Ohio, USA., Pepine CJ; Department of Medicine, Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA., Mitrani RD; Department of Medicine, Cardiovascular Division, University of Miami, Miller School of Medicine, Miami, Florida, USA., Hare JM; Department of Molecular and Cellular Pharmacology, Division of Cardiology, University of Miami, Miller School of Medicine, Miami, Florida, USA., Murphy MP; Department of Surgery, Division of Vascular Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA., March KL; Department of Medicine, Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA., Ikram S; Department of Medicine, Division of Cardiovascular Medicine, University of Louisville, School of Medicine, Louisville, Kentucky, USA., Lee DP; Department of Medicine and Cardiovascular Institute, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA., O'Brien C; Department of Medicine and Cardiovascular Institute, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA., Durand JB; Department of Cardiology, Division of Internal Medicine, M.D. Anderson Cancer Center, Houston, Texas, USA., Miller K; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA., Lima JA; Department of Medicine, Cardiology Division, Johns Hopkins University, Baltimore, Maryland, USA., Ostovaneh MR; Department of Medicine, Cardiology Division, Johns Hopkins University, Baltimore, Maryland, USA., Ambale-Venkatesh B; Department of Medicine, Cardiology Division, Johns Hopkins University, Baltimore, Maryland, USA., Gee AP; Department of Pediatrics, Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA., Richman S; Department of Pediatrics, Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA., Taylor DA; Department of Regenerative Medicine Research, Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, USA., Sayre SL; Department of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Bettencourt J; Department of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Vojvodic RW; Department of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Cohen ML; Department of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Simpson LM; Department of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Lai D; Department of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Aguilar D; Department of Epidemiology, Human Genetics and Environmental Sciences, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Loghin C; Department of Medicine, Division of Cardiovascular Medicine, UTHealth University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA., Moyé L; Department of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Ebert RF; Division of Cardiovascular Sciences, Basic & Early Translational Research Program, National Institutes of Health, National Heart, Lung, and Blood Institute, Washington, DC, USA., Davis BR; Department of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA., Simari RD; Division of Cardiovascular Diseases, University of Kansas School of Medicine, Kansas City, Kansas, USA. |
| Corporate Authors: | Cardiovascular Cell Therapy Research Network (CCTRN) |
| Source: | JACC. CardioOncology [JACC CardioOncol] 2020 Nov; Vol. 2 (4), pp. 581-595. Date of Electronic Publication: 2020 Dec 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101761697 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-0873 (Electronic) Linking ISSN: 26660873 NLM ISO Abbreviation: JACC CardioOncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
